STEPHEN BARNARD HOWELL
Pilots at Nogales Dr, Del Mar, CA

6344324, Feb 5, 2002

Jan 7, 2000

09/479529

Stephen B. Howell - Del Mar CA
Xinjian Lin - San Diego CA
Dennis P. Gately - San Diego CA

Research Development Foundation - Carson City NV

C12Q 168

435 6, 435 29, 435366, 435371

The present invention features a novel cellular injury reporter system in which a chimeric gene containing the GADD153 promoter linked to the coding region of an enhanced green fluorescent protein (EGFP) gene was stably integrated into the genome of carcinoma cells. Activation of the GADD153 promoter was quantified using flow cytometric measurement of EGFP expression following drug exposure. This reporter system is suitable for high. throughput in vitro and in vivo screening for agents capable of producing cytotoxicity via a wide variety of different mechanisms, and can be utilized to investigate the relative potency of structurally related DNA adducts.

5807572, Sep 15, 1998

Jun 6, 1995

8/473019

Sinil Kim - Solana Beach CA
Stephen B. Howell - Del Mar CA

DepoTech Corporation - La Jolla CA

A61K 9127

424450

Disclosed are multivesicular liposomes containing biologically active substances, the multivesicular liposomes having defined size distribution, adjustable average size, adjustable internal chamber size and number, and a modulated rate of the biologically active substance in contrast to the previous art. The process comprises dissolving a lipid component in volatile organic solvents, adding an immiscible aqueous component containing at least one biologically active substance to be encapsulated, and adding to either or both the organic solvents and the lipid component, a hydrochloride effective to control the release rate of the biologically active substance from the multivesicular liposome, making a water-in-oil emulsion from the two components, immersing the emulsion into a second aqueous component, dividing the emulsion into small solvent spherules which contain even smaller aqueous chambers, and then removing the solvents to give an aqueous suspension of multivesicular liposomes encapsulating biologically active substances.

5583024, Dec 10, 1996

May 10, 1993

8/060091

Marlene D. McElroy - late of La Jolla CA
W. D. McElroy - San Diego CA
Donald R. Helinski - La Jolla CA
Keith V. Wood - San Diego CA
Jeffrey R. De Wet - Menlo Park CA
David W. Ow - San Francisco CA
Stephen H. Howell - Del Mar CA

The Regents of the University of California - Oakland CA

C12N 902, C12N 1553, C12N 1563

135189

A method is disclosed for producing a protein which expresses bioluminescence activity which involves combining two polydeoxyribonucleotides, one containing a continuous sequence of codons encoding a polypeptide which comprises a single covalently bonded molecular structure and which catalyzes the oxidation of insect luciferin to yield light and the other which causes DNA transcription, and obtaining the polypeptide by transcription and subsequent translation. The insect luciferin is derived from bioluminescent insect, preferably Diptera and Coleoptera (fireflies and beetles). Hybrid proteins are similarly formed by inclusion of an additional polydeoxyribonucleotide encoding for a second polypeptide such that their respective polypeptide-encoding reading frames form a continuous reading frame. Also disclosed is a method for quantitatively assaying a fluid for the presence of an unknown quantity of antigen using the hybrid proteins bonded to antibody directed against the antigen, determining luminescence after reaction of the antibody and antigen, and determining the amount of the antigens by comparison of the determined luminescence with the luminescence previously measured under equivalent conditions for equivalent hybrid proteins reacted under equivalent conditions with known amounts of the antigen.

5928926, Jul 27, 1999

Jul 1, 1996

8/674149

Stephen B. Howell - Del Mar CA
Robert E. Enns - Solana Beach CA
Peter Naredi - Varberg, SE

Research Development Foundation - Carson City NV

C12N 914, C12N 120, C12N 1500, C07H 2104

435195

The present invention provides DNA encoding a human ARSA-I protein selected from the group consisting of: (a) isolated DNA which encodes a human ARSA-I protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a human ARSA-I protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a human ARSA-I protein. Also provided are pharmaceutical compositions comprising human human ARSA-I protein and a pharmaceutically acceptable carrier and host cells transfected with the vector of the present invention said vector expressing a human ARSA-I protein.

2006001, Jan 26, 2006

Mar 28, 2005

11/091938

Timothy Cheng - Toronto, CA
Stephen Howell - Del Mar CA, US
Gerald Manorek - San Diego CA, US
Charles Berry - San Diego CA, US
Goli Samimi - Los Angeles CA, US

C12Q 1/68

435006000

The present invention relates generally to the fields of molecular biology and medicine. More particularly, it concerns cancer treatments and the identification and use of markers for cancer resistance to a platinum-drug based therapy therapy. In certain embodiments, the present invention provides diagnostic and/or prognostic methods involving a collection of differentially expressed genes that may be used to identify cisplatin resistance in human ovarian cancer.

5674713, Oct 7, 1997

Jun 2, 1995

8/460214

Marlene DeLuca McElroy - late of La Jolla CA
Donald Raymond Helinski - La Jolla CA
Keith Vernon Wood - San Diego CA
Jeffrey Roux De Wet - Menlo Park CA
David Wing Ow - San Francisco CA
Stephen Herbert Howell - Del Mar CA

The Regents of the University of California - Oakland CA

C12N 121, C12N 510, C12N 1553, C12N 902

435 697

DNA compositions and methods of constructing and using the same consisting of DNA sequences encoding luciferase activity, or DNA sequences encoding hybrid molecules exhibiting luciferase activity and a second biological activity that are useful in performing biological assays.

5434046, Jul 18, 1995

Mar 8, 1993

8/029328

Robert E. Enns - Solano Beach CA
Stephen B. Howell - Del Mar CA

The Regents of the University of California - Oakland CA

C12Q 168, G01N 3353

435 6

This invention relates to DNA encoding drug resistance to cis-platin. The invention also includes expression products of, and vectors and hosts comprising the DNA sequence encoding cis-platin resistance. Also included are immunodiagnostic assays of cis-platin resistance and assays for screening materials having a modulating effect on DNA encoding the cis-platin resistance gene and on the expression product thereof. The invention is further directed to antagonists to the cis-platin resistance gene and the expression product thereof. Recombinant and pharmaceutical means making use of the cis-platin resistance gene and its expression product are also provided.

5597798, Jan 28, 1997

Mar 11, 1994

8/212110

Stephen B. Howell - Del Mar CA
Randolph D. Christen - San Diego CA
Seiji Isonishi - Suginami-Ku, JP
Paul A. Andrews - Washington Grove MD

The Regents of the University of California - Oakland CA

A61K 3700, A61K 31225

514 12

The present invention comprises a method of sensitizing various types of cancer cells derived from different tissues of origin to various cytotoxic agents and augmenting the sensitivity of cancer cells to these cytotoxic agents. The invention provides a method to treat cancer and other cell proliferative diseases by the administration of a sensitizing agent prior to or concurrently with the administration of a cytotoxic agent.

5455044, Oct 3, 1995

May 14, 1993

8/062799

Sinil Kim - Solana Beach CA
Stephen B. Howell - Del Mar CA

DepoTech Corporation - LaJolla CA

A61K 3800

424450

A method for ameliorating a neurological disorder in a human by administration to the cerebrospinal fluid (CSF) of a therapeutic agent in a dispersion system which allows the therapeutic agent to persist in the cerebro-ventricular space.

5576018, Nov 19, 1996

Jun 7, 1995

8/484501

Sinil Kim - Solana Beach CA
Stephen B. Howell - Del Mar CA

DepoTech Corporation - San Diego CA

A61K 9127

424450

A method for ameliorating a neurological disorder in a human by administration to the cerebrospinal fluid (CSF) of a therapeutic agent in a dispersion system which allows the therapeutic agent to persist in the cerebro-ventricular space.